The J-ALEX trial compared the efficacy and safety of alectinib versus crizotinib in japanese ALK-positive advanced or recurrent NSCLC patients with no prior ALK inhibition therapy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.